Novel treatments of autosomal dominant polycystic kidney disease

about

Patient Survey of current water Intake practices in autosomal dominant Polycystic kidney disease: the SIPs survey.Independent Role of Underlying Kidney Disease on Renal Prognosis of Patients with Chronic Kidney Disease under Nephrology Care.

P2860

Q33783023-86DEB960-63E1-49A3-B5AA-2EC333594A72 Q35628810-F671717B-DA6C-4D9C-A828-C18BB0E6CE02

P2860

Novel treatments of autosomal dominant polycystic kidney disease

Item

http://www.wikidata.org/entity/Q42556481

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Novel treatments of autosomal dominant polycystic kidney disease

@en

Novel treatments of autosomal dominant polycystic kidney disease

@nl

type

Item

label

Novel treatments of autosomal dominant polycystic kidney disease

@en

Novel treatments of autosomal dominant polycystic kidney disease

@nl

prefLabel

Novel treatments of autosomal dominant polycystic kidney disease

@en

Novel treatments of autosomal dominant polycystic kidney disease

@nl

P1476

Novel treatments of autosomal dominant polycystic kidney disease

@en

P2093

Rex L Mahnensmith

http://www.w3.org/2001/XMLSchema#string

P2860

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

The HALT polycystic kidney disease trials: design and implementation.

Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study.

Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease.

Hypertension in autosomal dominant polycystic kidney disease.

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

Sirolimus therapy to halt the progression of ADPKD.

Clinical practice. Autosomal dominant polycystic kidney disease.

Treatment strategies and clinical trial design in ADPKD

The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease

P304

831-836

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.2215/CJN.02480314

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24721886

http://www.w3.org/2001/XMLSchema#string

P921

autosomal dominant polycystic kidney disease

P932

4011435

http://www.w3.org/2001/XMLSchema#string

Novel treatments of autosomal dominant polycystic kidney disease

about

P2860

P2860

Novel treatments of autosomal dominant polycystic kidney disease

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932